Your browser doesn't support javascript.
loading
Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus.
Janssen, Julia M; Heyward, William L; Martin, J Tyler; Janssen, Robert S.
Afiliação
  • Janssen JM; Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, CA 94710-2753, United States.
  • Heyward WL; Quattro Clinical Research, Oakland, CA 94609, United States.
  • Martin JT; Adjuvance Technologies, Inc., New York, NY, United States.
  • Janssen RS; Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, CA 94710-2753, United States. Electronic address: rjanssen@dynavax.com.
Vaccine ; 33(7): 833-7, 2015 Feb 11.
Article em En | MEDLINE | ID: mdl-25576215
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Hepatite B / Diabetes Mellitus Tipo 2 / Insuficiência Renal Crônica / Receptor Toll-Like 9 / Hepatite B Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Hepatite B / Diabetes Mellitus Tipo 2 / Insuficiência Renal Crônica / Receptor Toll-Like 9 / Hepatite B Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article